Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

M. R. Matrana, C. Duran, A. Shetty, L. Xiao, B. J. Atkinson, P. Corn, L. C. Pagliaro, R. E. Millikan, C. Charnsangave, E. Jonasch, N. M. Tannir

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Aim The multi-tyrosine kinase inhibitor pazopanib prolongs progression-free survival (PFS) versus placebo in treatment-naive and cytokine-refractory metastatic clear-cell renal cell carcinoma (ccRCC). Outcomes and safety data with pazopanib after targeted therapy (TT) are limited. Methods We retrospectively evaluated records of consecutive patients with metastatic ccRCC who had progressive disease (PD) after TT and received pazopanib from November 2009 through November 2011. Tumour response was assessed by a blinded radiologist using Response Evaluation Criteria In Solid Tumours (RECIST). PFS and overall survival (OS) were estimated by Kaplan-Meier methods. Results Ninety-three patients were identified. Median number of prior TTs was 2 (range, 1-5). There were 68 events (PD or death). Among 85 evaluable patients, 13 (15%) had a partial response. Median PFS was 6.5 months (95% CI: 4.5-9.7); median OS was 18.1 months (95% CI: 10.26-NA). Common adverse events (AEs) included fatigue (44%), elevated transaminases (35%), diarrhoea (30%), hypothyroidism (18%), nausea/vomiting (17%), anorexia (14%) and hypertension exacerbation (14%); 91% of AEs were grade 1/2. Eleven patients (12%) discontinued therapy due to AEs. There were no treatment-related deaths. Concluding statement Pazopanib demonstrated efficacy in patients with metastatic ccRCC after PD with other TTs. Toxicity overall was mild/moderate and manageable.

Original languageEnglish (US)
Pages (from-to)3169-3175
Number of pages7
JournalEuropean Journal of Cancer
Volume49
Issue number15
DOIs
StatePublished - Oct 1 2013
Externally publishedYes

Fingerprint

Disease Progression
Disease-Free Survival
Therapeutics
Survival
Anorexia
Hypothyroidism
Transaminases
Protein-Tyrosine Kinases
Nausea
Vomiting
Fatigue
Diarrhea
Placebos
Clear-cell metastatic renal cell carcinoma
pazopanib
Cytokines
Hypertension
Safety
Neoplasms

Keywords

  • Angiogenesis
  • Mammalian target of rapamycin
  • Metastatic renal cell carcinoma
  • Pazopanib
  • Targeted therapy
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. / Matrana, M. R.; Duran, C.; Shetty, A.; Xiao, L.; Atkinson, B. J.; Corn, P.; Pagliaro, L. C.; Millikan, R. E.; Charnsangave, C.; Jonasch, E.; Tannir, N. M.

In: European Journal of Cancer, Vol. 49, No. 15, 01.10.2013, p. 3169-3175.

Research output: Contribution to journalArticle

Matrana, MR, Duran, C, Shetty, A, Xiao, L, Atkinson, BJ, Corn, P, Pagliaro, LC, Millikan, RE, Charnsangave, C, Jonasch, E & Tannir, NM 2013, 'Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies', European Journal of Cancer, vol. 49, no. 15, pp. 3169-3175. https://doi.org/10.1016/j.ejca.2013.06.003
Matrana, M. R. ; Duran, C. ; Shetty, A. ; Xiao, L. ; Atkinson, B. J. ; Corn, P. ; Pagliaro, L. C. ; Millikan, R. E. ; Charnsangave, C. ; Jonasch, E. ; Tannir, N. M. / Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. In: European Journal of Cancer. 2013 ; Vol. 49, No. 15. pp. 3169-3175.
@article{79b3e311a62c4030b8cef5c1a2ce8fe6,
title = "Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies",
abstract = "Aim The multi-tyrosine kinase inhibitor pazopanib prolongs progression-free survival (PFS) versus placebo in treatment-naive and cytokine-refractory metastatic clear-cell renal cell carcinoma (ccRCC). Outcomes and safety data with pazopanib after targeted therapy (TT) are limited. Methods We retrospectively evaluated records of consecutive patients with metastatic ccRCC who had progressive disease (PD) after TT and received pazopanib from November 2009 through November 2011. Tumour response was assessed by a blinded radiologist using Response Evaluation Criteria In Solid Tumours (RECIST). PFS and overall survival (OS) were estimated by Kaplan-Meier methods. Results Ninety-three patients were identified. Median number of prior TTs was 2 (range, 1-5). There were 68 events (PD or death). Among 85 evaluable patients, 13 (15{\%}) had a partial response. Median PFS was 6.5 months (95{\%} CI: 4.5-9.7); median OS was 18.1 months (95{\%} CI: 10.26-NA). Common adverse events (AEs) included fatigue (44{\%}), elevated transaminases (35{\%}), diarrhoea (30{\%}), hypothyroidism (18{\%}), nausea/vomiting (17{\%}), anorexia (14{\%}) and hypertension exacerbation (14{\%}); 91{\%} of AEs were grade 1/2. Eleven patients (12{\%}) discontinued therapy due to AEs. There were no treatment-related deaths. Concluding statement Pazopanib demonstrated efficacy in patients with metastatic ccRCC after PD with other TTs. Toxicity overall was mild/moderate and manageable.",
keywords = "Angiogenesis, Mammalian target of rapamycin, Metastatic renal cell carcinoma, Pazopanib, Targeted therapy, Tyrosine kinase inhibitor",
author = "Matrana, {M. R.} and C. Duran and A. Shetty and L. Xiao and Atkinson, {B. J.} and P. Corn and Pagliaro, {L. C.} and Millikan, {R. E.} and C. Charnsangave and E. Jonasch and Tannir, {N. M.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.ejca.2013.06.003",
language = "English (US)",
volume = "49",
pages = "3169--3175",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "15",

}

TY - JOUR

T1 - Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

AU - Matrana, M. R.

AU - Duran, C.

AU - Shetty, A.

AU - Xiao, L.

AU - Atkinson, B. J.

AU - Corn, P.

AU - Pagliaro, L. C.

AU - Millikan, R. E.

AU - Charnsangave, C.

AU - Jonasch, E.

AU - Tannir, N. M.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Aim The multi-tyrosine kinase inhibitor pazopanib prolongs progression-free survival (PFS) versus placebo in treatment-naive and cytokine-refractory metastatic clear-cell renal cell carcinoma (ccRCC). Outcomes and safety data with pazopanib after targeted therapy (TT) are limited. Methods We retrospectively evaluated records of consecutive patients with metastatic ccRCC who had progressive disease (PD) after TT and received pazopanib from November 2009 through November 2011. Tumour response was assessed by a blinded radiologist using Response Evaluation Criteria In Solid Tumours (RECIST). PFS and overall survival (OS) were estimated by Kaplan-Meier methods. Results Ninety-three patients were identified. Median number of prior TTs was 2 (range, 1-5). There were 68 events (PD or death). Among 85 evaluable patients, 13 (15%) had a partial response. Median PFS was 6.5 months (95% CI: 4.5-9.7); median OS was 18.1 months (95% CI: 10.26-NA). Common adverse events (AEs) included fatigue (44%), elevated transaminases (35%), diarrhoea (30%), hypothyroidism (18%), nausea/vomiting (17%), anorexia (14%) and hypertension exacerbation (14%); 91% of AEs were grade 1/2. Eleven patients (12%) discontinued therapy due to AEs. There were no treatment-related deaths. Concluding statement Pazopanib demonstrated efficacy in patients with metastatic ccRCC after PD with other TTs. Toxicity overall was mild/moderate and manageable.

AB - Aim The multi-tyrosine kinase inhibitor pazopanib prolongs progression-free survival (PFS) versus placebo in treatment-naive and cytokine-refractory metastatic clear-cell renal cell carcinoma (ccRCC). Outcomes and safety data with pazopanib after targeted therapy (TT) are limited. Methods We retrospectively evaluated records of consecutive patients with metastatic ccRCC who had progressive disease (PD) after TT and received pazopanib from November 2009 through November 2011. Tumour response was assessed by a blinded radiologist using Response Evaluation Criteria In Solid Tumours (RECIST). PFS and overall survival (OS) were estimated by Kaplan-Meier methods. Results Ninety-three patients were identified. Median number of prior TTs was 2 (range, 1-5). There were 68 events (PD or death). Among 85 evaluable patients, 13 (15%) had a partial response. Median PFS was 6.5 months (95% CI: 4.5-9.7); median OS was 18.1 months (95% CI: 10.26-NA). Common adverse events (AEs) included fatigue (44%), elevated transaminases (35%), diarrhoea (30%), hypothyroidism (18%), nausea/vomiting (17%), anorexia (14%) and hypertension exacerbation (14%); 91% of AEs were grade 1/2. Eleven patients (12%) discontinued therapy due to AEs. There were no treatment-related deaths. Concluding statement Pazopanib demonstrated efficacy in patients with metastatic ccRCC after PD with other TTs. Toxicity overall was mild/moderate and manageable.

KW - Angiogenesis

KW - Mammalian target of rapamycin

KW - Metastatic renal cell carcinoma

KW - Pazopanib

KW - Targeted therapy

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84884902024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884902024&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2013.06.003

DO - 10.1016/j.ejca.2013.06.003

M3 - Article

C2 - 23810246

AN - SCOPUS:84884902024

VL - 49

SP - 3169

EP - 3175

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 15

ER -